Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program

CONCLUSION: The duration of each previous PFS is a major prognostic factor for OS in mTNBC patients receiving third- or fourth-line chemotherapy. The clinical utility of nomograms including this information was not demonstrated.PMID:33561617 | PMC:PMC7873471 | DOI:10.1016/j.breast.2021.01.006
Source: Breast - Category: Cancer & Oncology Authors: Source Type: research